BIIB
BIOGEN INC.
BIOGEN INC. (BIIB) has 11 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Jun 11, 2026.
- Industry:Drug Manufacturers - General
- CEO:Christopher A. Viehbacher
- Employees:7,605
- HQ:Cambridge, MA, US
- IPO:1991-09-17
No open-market insider trades for BIIB (BIOGEN INC.) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Congress trading BIIB
See timeline →- RRep. Maria Elvira SalazarSale$15,001 - $50,0002026-06-02
- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-06-05
- RRep. Maria Elvira SalazarPurchase$50,001 - $100,0002026-05-11
- RRep. Maria Elvira SalazarPurchase$1,001 - $15,0002026-05-11
- RRep. Maria Elvira SalazarPurchase$1,001 - $15,0002026-05-12
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
BIOGEN INC. is in the Healthcare sector.